Sucampo Appoints Barbara A. Munder and Maureen E. O’Connell to Board of Directors

  Sucampo Appoints Barbara A. Munder and Maureen E. O’Connell to Board of

Business Wire

BETHESDA, Md. -- March 1, 2013

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced it
appointed Barbara A. Munder, senior advisor to Euromoney Institutional
Investor PLC, and Maureen E. O’Connell, executive vice president, chief
administrative officer and chief financial officer of Scholastic Corporation
(NASDAQ: SCHL), to its board of directors.

“Barbara and Maureen collectively bring a strong mix of operational, financial
and marketing expertise from a variety of public and private companies, which
we believe will further benefit Sucampo and our shareholders during this
important time of growth for our company,” said Sucampo’s Chairman, Chief
Executive Officer, and Chief Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D.

Ms. Munder serves as senior advisor to Euromoney Institutional Investor PLC,
an international business-to-business publisher, and brings considerable
operational, strategy, and marketing expertise to Sucampo’s board. She was
previously executive director of the operating groups Institutional Investor
Institute and The Hedge Fund Institutional Forum. Prior to joining Euromoney
Institutional Investor, Ms. Munder served as chief operating officer at
Womenfuture LLC, a distance learning company, where she oversaw e-business
strategy. She also served over 24 years in various roles with The McGraw-Hill
Companies, Inc. (NYSE: MHP), among them Senior Vice President, New
Initiatives; Vice President and General Manager, Business Week Services; and
Vice President, Business Development, Business Week Group.

Ms. Munder also serves as a director of PETsMART Inc. (NASDAQ: PETM) and
Munder Realty Corporation, a private real estate firm. Additionally, she has
been on the advisory board for DOAR, a private litigation information services
and consulting firm; Izzo Systems, a manufacturer of ergonomically designed
golf bags and straps; and Lighthouse International, a non-profit for the
visually impaired.

Ms. O’Connell brings a strong background in finance and operations to
Sucampo’s board, gleaned from her experience as a chief financial officer in
seven companies. In her current role at Scholastic Corporation, Ms. O’Connell
has overall responsibility for finance, human resources, information
technology, customer service, facilities, supply chain, and manufacturing.
Since joining the company, she has been a key partner with all business units
to better align support functions while enhancing visibility to operating
trends and leading business indicators. In her 23 years of experience, she has
served as chief financial officer, chief administrative officer, chief
operating officer, and president for both private and public companies
including Affinion Group, Inc., a leading affinity direct marketer of
membership, insurance and loyalty programs; Gartner, Inc. (NYSE: IT), a
leading technology research and advisory firm; Barnes & Nobel (NYSE: BKS);
Publishers Clearing House; and BMG Direct.

Ms. O’Connell is a former member of the board of directors of Beazer Homes
(NYSE: BZH), where she served as audit chair for most of her tenure.

Sucampo also announced that Timothy I. Maudlin informed the Company he has
decided to resign his position from the Sucampo Board, effective February 25,
2013. Maudlin became a director in September 2006.

“On behalf of our board of directors, I would like to thank Tim for his
contributions to Sucampo over the past six years,” said Dr. Ueno. “We are
grateful for his leadership and wish him well in his future endeavors.”

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s chairman,
chief executive officer, chief scientific officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or regulatory

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo's
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo's most recent Form 8-K and 10-K, which the Company
incorporates by reference.


Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
Press spacebar to pause and continue. Press esc to stop.